A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Preliminary Efficacy of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Latest Information Update: 29 Sep 2023
At a glance
- Drugs NTQ 2494 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Nanjing Chia Tai Tianqing Pharmaceutical
Most Recent Events
- 29 Sep 2023 New trial record